HomeDMYD-B • STO
add
Diamyd Medical AB
Previous close
kr 17.62
Day range
kr 17.16 - kr 17.72
Year range
kr 7.50 - kr 17.88
Market cap
2.34B SEK
Avg Volume
626.39K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Nov 2025info | Y/Y change |
|---|---|---|
Revenue | 245.00K | 842.31% |
Operating expense | 48.14M | 15.02% |
Net income | -48.84M | -35.07% |
Net profit margin | -19.94K | 85.67% |
Earnings per share | — | — |
EBITDA | -47.06M | -13.67% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Nov 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 233.18M | 52.53% |
Total assets | 302.46M | 35.70% |
Total liabilities | 70.82M | 6.05% |
Total equity | 231.64M | — |
Shares outstanding | 137.50M | — |
Price to book | 10.49 | — |
Return on assets | -37.27% | — |
Return on capital | -47.73% | — |
Cash Flow
Net change in cash
| (SEK) | Nov 2025info | Y/Y change |
|---|---|---|
Net income | -48.84M | -35.07% |
Cash from operations | -43.70M | -4.49% |
Cash from investing | -20.10M | -183.55% |
Cash from financing | 7.00K | -99.99% |
Net change in cash | -63.85M | -259.15% |
Free cash flow | -27.48M | 11.67% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
41
